title: Inhaled fluticasone reduces bronchial responsiveness and airway inflammation in cats with mild chronic bronchitis.
abstract: This study investigated the effect of inhaled fluticasone on lower airway inflammation and bronchial responsiveness (BR) to inhaled carbachol in cats with very mild, chronic bronchitis (n = 5) that were compared with healthy cats serving as controls (n = 6). Chest radiographs, BR tests performed non-invasively by barometric whole body plethysmography (BWBP) and bronchoalveolar lavage (BAL) were performed before and after treatment. BR was quantified by calculating the concentration of carbachol inducing bronchoconstriction (C-Penh300%), defined as a 300% increase of baseline Penh, an index of bronchoconstriction obtained by BWBP. BAL fluid was analyzed cytologically and the oxidant marker 8-iso-PGF2alpha was determined. At test 1, healthy cats and cats with bronchitis were untreated, whereas for test 2 inhalant fluticasone (250 microg once daily) was administrated for 2 consecutive weeks to cats with bronchitis. Control cats remained untreated. Inhaled fluticasone induced a significant increase in C-Penh300% and a significant decrease of BAL fluid total cells, macrophages, neutrophils and 8-iso-PGF2alpha in cats with bronchitis, whilst untreated control cats did not show significant changes over time. This study shows that a 2-week fluticasone treatment significantly reduced lower airway inflammation in very mild bronchitis. BR could be successfully monitored in cats using BWPB and decreased significantly in response to inhaled fluticasone. 8-Iso-PGF2alpha in BAL fluid was responsive to treatment and appeared as a sensitive biomarker of lower airway inflammation in cats.
authors.affiliation: Department for Functional Sciences B41, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium. kirschvink@fundp.ac.be
authors.forename: Nathalie
authors.initials: N
authors.lastname: Kirschvink
authors.forename: Jérôme
authors.initials: J
authors.lastname: Leemans
authors.forename: François
authors.initials: F
authors.lastname: Delvaux
authors.forename: Frédéric
authors.initials: F
authors.lastname: Snaps
authors.forename: Séverine
authors.initials: S
authors.lastname: Jaspart
authors.forename: Brigitte
authors.initials: B
authors.lastname: Evrard
authors.forename: Luc
authors.initials: L
authors.lastname: Delattre
authors.forename: Carole
authors.initials: C
authors.lastname: Cambier
authors.forename: Cécile
authors.initials: C
authors.lastname: Clercx
authors.forename: Pascal
authors.initials: P
authors.lastname: Gustin
mesh_terms: D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D029481:Bronchitis, Chronic / Q000188:drug therapy / Q000662:veterinary*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D005260:Female; D000068298:Fluticasone; D008297:Male; D010991:Plethysmography / Q000662:veterinary; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D000068298:Fluticasone